7 June 2021 (Monday) - BTLP-TACT Excercise

Time for another BTLP-TACT exercise. I approach these with something of a sense of dread…

The software presented me with one case – an eighty-year old chap from the renal unit requiring group & save.
He grouped as O Rh(D) Positive with a negative antibody screen.

I got the green light.

5 June 2021 (Saturday) - ASH Update

The American Society of Hematology sent two updates today. One on lymphoma and lymphoid neoplasms, and one from the 2021 ASCO Annual Meeting:

 

Topic Compilations 

Our Topic Compilations collect features and news articles published in ASH Clinical News related to a specific hematologic disorder, including bleeding disorders, chronic leukemias, multiple myeloma, and more. Here are the highlights in lymphomas and lymphoid neoplasia:

Umbralisib Demonstrates Long-Term Safety and Clinical Activity in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma New study results published in the Journal of Clinical Oncology suggest treatment with the PI3K and casein kinase-1ε inhibitor led to meaningful clinical activity and a manageable safety profile in this patient population.

International Prognostic Tool Predicts Outcomes in Angioimmunoblastic T-Cell Lymphoma Researchers have created a novel prognostic score, described in a recent Blood paper, which stratifies patients into low-, intermediate-, and high-risk subgroups for overall survival.

Are Survivors of Childhood Lymphomas At Increased Risk of Cognitive Impairment?
A recent study suggests the systemic therapies that survivors of pediatric cancers receive may impact their long-term cognitive outcomes, with negative effects on education, employment, and income

 

 

On Location

ASH Clinical News is following the 2021 ASCO Annual Meeting to report on the latest advances in hematologic malignancies. Here’s a look at some of the highlights:

Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies
Treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high rates of complete responses in patients with acute myeloid leukemia.

Can Participation in Cancer Clinical Trials Save Money?
Patients with cancer who were treated as part of a clinical trial had lower costs of care than similar patients who were receiving routine care, according to an analysis from a large community-based oncology practice.

Functional, Nutritional, and Social Status Predict Survival Outcomes in Older Patients with CLL
These geriatric domains were associated with overall survival and progression-free survival in older adults with chronic lymphocytic leukemia.

 

4 June 2021 (Friday) - IBMS Newsletter

The IBMS sent their newsletter today. I mention it because I feel I should…